Iambic Therapeutics
San Diego AI small-molecule biotech running weekly automated design-make-test loops; lead HER2 drug in Phase 1/1b, IPO pending as "IAM".
1. Core Product / Service
Iambic (founded 2019) is a pipeline company, not a software vendor: its AI stack (including the NeuralPLexer structure-prediction model) is used to discover its own small molecules, which it takes into the clinic itself [1]. The lead asset, IAM1363, is an oral, brain-penetrant HER2 inhibitor in a Phase 1/1b basket trial, with a registrational study targeted for as early as 2027; IAM217 (KIF18A) and IAM-C1 (CDK2/4) were slated for IND filings in Q4 2026 [1]. The company says IAM1363 went from project start to clinical development in about two years [1].
Wet lab. The S-1 describes an in-house automated chemistry and biology platform: micro- and nanoscale synthesis in 96/384/1536-well plates run weekly, covering ~90% of common med-chem transformations, plus automated biochemical, cellular, metabolic and physicochemical assays that drive weekly active-learning loops — "hundreds of compounds per program on a weekly cadence" [1]. There is no in-house cryo-EM or crystallography; structural information comes from prediction [1].
| Wet-lab metric | Value |
|---|---|
| Current lab + office | ~12,545 sf, San Diego [1] |
| New HQ (Cray Court) | ~95,985 sf, phased occupancy from late 2026; ~$40.7M lease commitments [1] |
| Headcount | 171 FTE, 140 in R&D (2026-09-18) [1] |
| Lab equipment (gross) | ~$8.5M; PP&E net $4.8M [1] |
| Outsourced | GMP drug substance/product to CDMOs (manufacturing concentrated in China-based or China-affiliated CMOs; single CMO for IAM1363 API); WuXi AppTec for "certain R&D services"; clinical trials via CROs [1] |
2. Target Users & Pain Points
- Patients / its own pipeline: oncology programs where brain penetration (HER2) or hard-to-hit targets (KIF18A, solved without a high-resolution experimental structure) matter [1].
- Pharma partners: AbbVie, Takeda and Lundbeck collaborations; nvidia is both technology partner and shareholder [1].
- Pain addressed: the med-chem design-make-test cycle is slow and labor-bound; Iambic's claim is that a closed robotic loop plus models retrained weekly shortens the path to a development candidate.
3. Competitive Landscape
| Player | Approach | Vs. Iambic |
|---|---|---|
| recursion-pharmaceuticals | Phenomics HTS + automated chemistry, ~200k+ sf labs | Far heavier lab footprint; Iambic is chemistry-first |
| schrodinger | Physics-based software, no wet lab, CRO synthesis | Sells the tools Iambic builds in-house; also cited as an AI-layer competitor |
| isomorphic-labs | AlphaFold-lineage small molecules, CRO-network chemistry | Similar target class, opposite make/buy choice |
| generate-biomedicines | Biologics, ~146k sf in-house lab | Proteins vs small molecules; both outsource manufacturing |
4. Unique Observations
- "Scale without lab space" vs. a 7.6x lease: the S-1 says the platform is "designed to scale without needing proportional increases in headcount, lab space", yet the company is moving from ~12.5k sf to ~96k sf. At current occupancy it runs ~73 sf per employee; the new site implies ~560 sf/employee, in line with generate-biomedicines [1].
- Light-capex expansion: PP&E of only $4.8M against a ~$40.7M lease suggests growth is financed by leases and landlord concessions (32 months of free base rent on the initial premises) rather than heavy equipment purchases [1].
- In-house discovery, outsourced everything downstream: the S-1 states internal labs own early, milligram-scale synthesis while CDMOs execute GMP synthesis — and it flags BIOSECURE as a risk given China-based manufacturing [1]. This is the clearest written statement of the "build the data engine, rent the factory" pattern among US AI biotechs.
5. Financials / Funding
- Private capital: ~$462M raised through 2026-09-18; >5% holders include Catalio, Nexus, Q Healthcare, NVIDIA and Coatue [1].
- Spend: FY2025 R&D $77.5M (FY2024 $45.7M); 1H 2026 R&D $57.1M [1]. Net loss $94.25M on $18.25M collaboration revenue for the 12 months to 2026-06-30 [2].
- IPO: S-1 filed publicly 2026-09-21 (Nasdaq: IAM; JPM, Jefferies, BofA, Citi). Terms set in October:
9.38M shares at $15–17, valuation up to ~$806M at the top of the range; ARK and Duquesne indicated ~$60M of interest; $75M of proceeds earmarked for IAM1363 [2][3]. As of 2026-10-14 no final pricing was confirmed; outlets differ on the midpoint raise ($135M vs ~$150M; up to ~$160M with options) [2][3].
6. People & Relationships
- Founders / management: Tom Miller (CEO, ex-Caltech professor), Fred Manby (CTO, ex-University of Bristol), Peter Olson (CSO, ex-Mirati/Pfizer), Michael Secora (CFO, ex-Recursion), Neil Josephson (CMO) [1].
- Sites: San Diego HQ and lab; offices in Massachusetts, Virginia, Bristol (UK) and Dublin [1].
- Partners / investors: nvidia, AbbVie, Takeda, Lundbeck; Catalio, Coatue.
- Peers: recursion-pharmaceuticals, isomorphic-labs, schrodinger, generate-biomedicines, absci, insitro.
Sources
- [1] Iambic Therapeutics Form S-1 (2026-09-21) and S-1/A (2026-10-08), SEC EDGAR (2026-10-14)
- [2] pharmaphorum, "Iambic prices its IPO, seeking to raise up to $160m" (2026-10-09; accessed 2026-10-14); The Star / Reuters, "Nvidia-backed Iambic Therapeutics launches IPO" (2026-10-09; accessed 2026-10-14)
- [3] Renaissance Capital, "Iambic Therapeutics sets terms for $150 million IPO" (2026-10-14)